CD40 ligand gene-modified autologous skin fibroblasts + interleukin-2 gene-modified autologous leukemic blasts

This investigational autologous cancer vaccine, developed by Baylor College of Medicine, is designed for the treatment of high-risk acute leukemia and myelodysplastic syndrome (MDS). The therapy involves harvesting a patient's own skin fibroblasts and leukemic blast cells. The fibroblasts are genetically modified using adenoviral vectors to express human CD40 ligand (CD40L) and interleukin-2 (IL-2). These modified fibroblasts are then mixed with the patient's autologous leukemic cells and administered as an immunotherapy. CD40L provides costimulatory signals by binding to CD40 receptors on leukemic cells and antigen-presenting cells, while IL-2 stimulates the proliferation and activation of antileukemic T-cells. This combination is intended to enhance the body's ability to recognize and destroy residual leukemic cells following standard treatments like chemotherapy or stem cell transplantation.

Other names

CD40L and IL-2 Gene-Modified Autologous Fibroblasts and Tumor CellsCD-40L and IL-2 Gene-Modified Autologous Fibroblasts and Tumor CellsCD 40L and IL-2 Gene-Modified Autologous Fibroblasts and Tumor CellsCD40 ligand gene-modified autologous skin fibroblasts + interleukin-2 gene-modified autologous leukemic blasts-Baylor College of Medicine-leukemia-myelodysplastic syndrome